Immune Design Corp. (NASDAQ:IMDZ) issued its quarterly earnings results on Wednesday. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.11. The business earned $8.20 million during the quarter, compared to the consensus estimate of $1.73 million. Immune Design Corp. had a negative return on equity of 52.07% and a negative net margin of 415.05%.

Shares of Immune Design Corp. (NASDAQ:IMDZ) opened at 8.25 on Friday. The company’s 50 day moving average price is $6.97 and its 200-day moving average price is $8.68. The firm’s market cap is $209.62 million. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $23.55.

Earnings History for Immune Design Corp. (NASDAQ:IMDZ)

In related news, Director Lewis W. Coleman purchased 40,000 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were bought at an average price of $6.25 per share, for a total transaction of $250,000.00. Following the acquisition, the director now directly owns 50,000 shares in the company, valued at $312,500. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Group L. P. Column purchased 800,000 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were bought at an average price of $6.25 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here. 42.90% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of IMDZ. Swiss National Bank increased its stake in shares of Immune Design Corp. by 14.7% in the second quarter. Swiss National Bank now owns 12,500 shares of the company’s stock valued at $102,000 after buying an additional 1,600 shares during the period. ProShare Advisors LLC increased its stake in shares of Immune Design Corp. by 1.1% in the second quarter. ProShare Advisors LLC now owns 16,372 shares of the company’s stock valued at $134,000 after buying an additional 185 shares during the period. Highbridge Capital Management LLC bought a new stake in shares of Immune Design Corp. during the second quarter valued at $215,000. Alps Advisors Inc. increased its stake in shares of Immune Design Corp. by 25.0% in the second quarter. Alps Advisors Inc. now owns 28,310 shares of the company’s stock valued at $231,000 after buying an additional 5,657 shares during the period. Finally, California State Teachers Retirement System increased its stake in shares of Immune Design Corp. by 25.1% in the third quarter. California State Teachers Retirement System now owns 29,374 shares of the company’s stock valued at $223,000 after buying an additional 5,900 shares during the period. Institutional investors own 47.66% of the company’s stock.

Several equities research analysts have weighed in on IMDZ shares. Jefferies Group reissued a “buy” rating and issued a $17.00 price target on shares of Immune Design Corp. in a report on Tuesday, October 25th. Zacks Investment Research raised Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 12th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $13.50.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

5 Day Chart for NASDAQ:IMDZ

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.